Overview
Binds to melanocortin receptors on immune cells in the intestinal mucosa.
Proposed mechanism
Tripeptide derived from α-MSH inhibiting NF-κB activation and reducing pro-inflammatory cytokines in gut.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
KPV in IBD models
· DOI:10.3389/fimmu.2018.00517 · 2018
- [2]
KPV in IBD models (2018)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.